![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NOVACAL LICENSES NOVEL ANTI-INFECTIVE COMPOUNDS FOR EYE, EAR AND SINUS INFECTIONS TO ALCON
NOVACAL LICENSES NOVEL ANTI-INFECTIVE COMPOUNDS FOR EYE, EAR AND SINUS INFECTIONS TO ALCON
NovaCal Pharmaceuticals Inc. ("NovaCal") announced that it has signed a collaboration and license agreement with an affiliate of Alcon, Inc., the world's leading eye care company, to research, develop and commercialize NovaCal's novel Aganocide compounds to treat infections of the eye, ear and sinus, including those associated with persistent bacterial biofilms.
Yahoo Finance (http://biz.yahoo.com/prnews/060918/sfm101.html?.v=52)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct